Status:
COMPLETED
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
Lead Sponsor:
Starpharma Pty Ltd
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
HSV-2 Genital Herpes
Eligibility:
FEMALE
18-45 years
Phase:
PHASE1
PHASE2
Brief Summary
To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up to 24 hours after a...
Eligibility Criteria
Inclusion
- Healthy women aged 18-45 with regular menstrual cycles, free from sexually transmitted infections and using adequate contraception
Exclusion
- Any condition, including genital conditions, sexually transmitted infection, menopause, and/or allergies that would make the study participant unsuitable for the study.
- Pregnancy or breast-feeding
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00740584
Start Date
August 1 2008
End Date
March 1 2009
Last Update
October 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nucleus Network
Melbourne, Australia